Navigation Links
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
Date:1/15/2014

An article published in the January issue of the International Journal of Radiation Oncology, Biology and Physics reports results of the Radiation Therapy Oncology Group (RTOG) phase II clinical trial of Bevacizumab (Avastin) in addition to cisplatin and pelvic radiation for locally advanced cervical cancer. The group reports that the addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.

"Cervical cancer is a huge problem worldwide, but isn't as big a problem in the United States. So in many ways it tends to become a somewhat overlooked and under-studied disease," says Tracey Schefter, MD, investigator at the University of Colorado Cancer Center, director of the Stereotactic Body Radiation Therapy program at the University of Colorado School of Medicine, and the study's lead author.

Risk factors for cervical cancer include infection with the human papilloma virus (HPV). Screening dramatically reduces both the likelihood of developing cervical cancer and the disease's mortality rate. Combined, these two factors mean that 80 percent of the world's approximately 473,000 yearly cases of cervical cancer occur in the developing world. In the United States, cervical cancer rates have dropped 74 percent over the previous 50 years, but is still diagnosed in approximately 10,000 women per year, with 3,500 deaths due to the disease.

The current phase II clinical trial enrolled 49 eligible patients from 28 institutions in the years 2006-2009. The study previously reported that Bevacizumab was safe and well-tolerated in combination with cisplatin and radiation therapy in this population. Now the group reports on the secondary efficacy endpoints at a median follow-up time of 3.8 years.

Specifically the group evaluated the addition of 10mg/kg bevacizumab every two weeks for 3 cycles during
'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
5. IDRI and Medicago announce authorization to initiate a Phase 1 clinical trial for an H5N1 vaccine
6. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
7. JDRF announces winners of first phase of Agnes Varis Glucose-Responsive Insulin Challenge
8. Positive results from Phase 1/2 stem cell trial reported
9. New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial
10. Teva to present new Phase III data for QNASL® Nasal Aerosol at the 2012 ACAAI Meeting
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Phase II trial of Bevacizumab (Avastin) in locally advanced cervical cancer 'promising'
(Date:2/26/2015)... The COR HEALTH division of Vets ... NY, to offer customers a full line of Topricin® ... safely and effectively address muscle, joint, and nerve pain. ... Access LLC, Montrose, MI, that is dedicated to providing ... BioMedics is a research and development leader in topical ...
(Date:2/26/2015)... February 26, 2015 The Reproductive Science ... their newly renovated office in Lawrenceville, NJ. ... Center of New Jersey’s physicians, and NJ Top Docs, ... care in the areas of infertility and reproductive medicine. ... excellent success rates and providing current, high quality medical ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Beckman Coulter ... of extracellular vesicles and their cargo in cell-to-cell communication,” ... and their relevance for cell-to-cell communication. The webinar is ... 4, 2015 at 8:00am PT. , Every cell in ... vesicles (EVs) , often called “exosomes” or “microvesicles.” These ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Body Well Therapy, ... ten years of delivering high quality mobile massage ... and other regions across the United States. The company has ... a pivotal year as it sets its sights on additional ... office chair massage services. , “We’ve come a long way ...
(Date:2/26/2015)... San Diego, Calif. (PRWEB) February 26, 2015 ... continues to soar as evidenced by a EuroMonitor ... top $6.5 billion in 2018. In response ... Bellus Academy’s Poway campus is launching a barbering ... Muldoon of San Diego’s “The Factory” salon. The ...
Breaking Medicine News(10 mins):Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 2Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 2Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 3Health News:Bellus Academy Partners with Renowned Hairstylist D.J. Muldoon to Launch Signature Barbering Program 2
... third quarter 2008 financial results before the market opens on Monday, November ... ... 2008 -- The company also plans to have a corporate overview ... on November 3, 2008 at 11:20 a.m. EST (8:20 a.m. PST). Michael ...
... the genome in the hope of ,finding genetic variants ... the wrong place, new research at the Stanford ,University ... as type-1 diabetes, is an autoimmune ,disease, caused when ... a person,s pancreas. , What triggers that immune response ...
... Voters in,September, As Well As Other Recent Public Polls ... Oct. 30 With only a few,days remaining before ... the Kaiser Family Foundation, writing for the November 6,2008, ... in ten,registered voters say major changes are needed in ...
... 30 AMN Healthcare Services,Inc. (NYSE: AHS ) today announced ... -- Revenue of $315 million, up 5% over last year and ... Company guidance. -- Revenue growth primarily driven by year-over-year volume ... Nurse & Allied and Locum Tenens. -- EPS of $0.28, ...
... Up 71% Versus Prior Year, As ... Company Generates $67.3 Million of Cash from Operating Activities in ... Third Quarter - ... DIEGO, Oct. 30 Gen-Probe Incorporated,(Nasdaq: GPRO ) today reported strong financial results for ...
... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced third quarter ... September 30, 2008, Nuvelo reported a net,loss of $8.5 million ... or $0.27 per share for the same period in 2007. ... net loss of $27.2 million or,$0.51 per share, compared with ...
Cached Medicine News:Health News: Dynavax to Report Third Quarter 2008 Financial Results : -- To Present at Oppenheimer's Healthcare Conference -- 2Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 2Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 3Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 4Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 2Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 3Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 4Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 2Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 3Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 4Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 5Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 6Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 7Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 8Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 9Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 10Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 11Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 12Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 13Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 14Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 15Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 2Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 3Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 4Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 5Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 6Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 7Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 8Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 9Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 10Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 11Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 12Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 13Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 14Health News:Nuvelo Reports Third Quarter 2008 Financial Results 2
(Date:2/26/2015)... MILFORD, Mass. , Feb. 26, 2015 /PRNewswire/ ... developing novel therapeutics for the treatment of Hepatitis ... announced the closing of a $22 million financing. ... of SB 9200, a novel, broad spectrum antiviral ... molecule nucleic acid hybrid (SMNH) chemistry platform, into ...
(Date:2/26/2015)... Feb. 26, 2015 The market for ... is estimated at 2.4 billion in 2014.   ... growth, government insurance, newly insured patients and updated ... and will continue to propel demand.  The healthcare market ... the market and interviews with IVD manufacturers and ...
(Date:2/26/2015)... -- Editor Note: For more information ... Investor-Edge has initiated coverage on the following equities: ... Pharmaceutical Industries Ltd (NYSE: TEVA ), Endo ... (NYSE: AGN ), and Depomed Inc. (NASDAQ: ... and Johnson can be accessed at http://get.Investor-Edge.com/pdf/?c=Johnson%20and%20Johnson&d=26-Feb-2015&s=JNJ . ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Completes $22 Million Financing 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 2Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 3Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 4Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 5
... Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... Oct. 4 Octapharma USA has ... at www.wilateusa.com to provide von Willebrand disease ... and updates. The U.S. Food and Drug Administration ... wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the ...
Cached Medicine Technology:Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 2Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 3Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 4Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 5Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 6Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: